MedTrace Logo

Effect of Celecoxib on Markers of Vascular Inflammation

NCT00471341 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2011-09-19

No results posted yet for this study

Summary

This study involves a drug called celecoxib, which is commonly prescribed for people with arthritis. Arthritis is caused by inflammation of the joints or tissues. Inflammation also occurs in the blood vessels that lead to your heart, and the purpose of this study is to see if celecoxib can reduce the blood vessel inflammation associated with high cholesterol and heart disease.

Conditions

  • Hypertension and Coronary Artery Disease

Interventions

DRUG

Celecoxib

DRUG

placebo

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Rhonda M Cooper-DeHoff, Pharm D · University of Florida Faculty

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471341 on ClinicalTrials.gov